Drug
Vidutolimod clinical trials
Also written CMP-001 and CYT 003.
- studies test it
- 16
- open now
- 0
- in phase 3
- 1
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 7 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 13
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 7
Regeneron Pharmaceuticals (7) · Diwakar Davar (2) · Cytos Biotechnology AG (2) · National Cancer Institute (NCI) (1) · Centre Hospitalier Universitaire Vaudois (1) · Emory University (1) · University of Southern California (1) · Umar Farooq (1)
Often tested with
Tested in the same studies.
Pembrolizumab (4) · Nivolumab (3) · Atezolizumab (1) · Cemiplimab (1) · Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 (1)
Studies
Open first, then newest update. How each study uses vidutolimod is read from its arms, and is right about nine times in ten.
Testing it · 16
- Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerSuspendedPhase 2Emory UniversityNCT05445609Written as VLP-encapsulated TLR9 Agonist CMP-001,
- A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04708418Written as VLP-encapsulated TLR9 Agonist CMP-001
- Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. NivolumabCompletedPhase 2Diwakar DavarNCT04401995Written as Vidutolimod (CMP-001)
- CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaTerminatedPhase 2/3Regeneron PharmaceuticalsNCT04695977Written as CMP-001
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedPhase 2Regeneron PharmaceuticalsNCT04916002Written as vidutolimod
- CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except MelanomaTerminatedPhase 1/2University of Southern CaliforniaNCT04387071Written as VLP-encapsulated TLR9 Agonist CMP-001
- CMP-001 for Relapsed and Refractory LymphomaTerminatedPhase 1/2Umar FarooqNCT03983668Written as CMP-001
- Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedPhase 1Regeneron PharmaceuticalsNCT02680184Written as CMP-001
- CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaTerminatedPhase 2Regeneron PharmaceuticalsNCT04698187Written as CMP-001
- CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseCompletedPhase 2Diwakar DavarNCT03618641Written as CMP-001
- CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 2Regeneron PharmaceuticalsNCT04633278Written as CMP-001
- CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)Active, not recruitingPhase 2Centre Hospitalier Universitaire VaudoisNCT04807192Written as CMP-001
- Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedPhase 1Regeneron PharmaceuticalsNCT03084640Written as CMP-001
- Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerCompletedPhase 1Regeneron PharmaceuticalsNCT03438318Written as CMP-001
- CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic AsthmaTerminatedPhase 2Cytos Biotechnology AGNCT01673672Written as CYT003
- CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled GlucocorticosteroidsWithdrawnPhase 2Cytos Biotechnology AGNCT02087644Written as CYT003
Given in every arm · 4 — vidutolimod is usual care beside what is tested
- A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)Not yet recruitingPhase 2Regeneron PharmaceuticalsNCT07808515Written as Vidutolimod
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as CMP 001
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedPhase 1/2PfizerNCT02554812Written as CMP-001
- Combined Immunotherapy and Radiosurgery for Metastatic Colorectal CancerCompletedPhase 1Sheba Medical CenterNCT03507699Written as CMP-001
Codes
What other systems call vidutolimod · ClinicalTrials.gg INT016294
- UNII (FDA) D68OW5RS98VIDUTOLIMODOne source FDA
- NCI Thesaurus C175875VidutolimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D68OW5RS98 | VIDUTOLIMOD | One source FDA |
| NCI Thesaurus | C175875 | Vidutolimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.